Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.41 |
| ▸ | VDR | P11473 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5515089 | 0.99 | L3MBTL1 (0.42) | L3MBTL1NR1H4VDRMAPTHPGD | |
| SCHEMBL14383790 | 0.96 | HPGD (0.46) | L3MBTL1NR1H4VDRMAPTHPGD | |
| Hydrochloric Acid SCHEMBL5508860 | 0.95 | HPGD (0.45) | L3MBTL1NR1H4VDRMAPTHPGD | |
| SCHEMBL14383795 | 0.95 | L3MBTL1 (0.44) | L3MBTL1NR1H4VDRMAPTCYP2C9 | |
| SCHEMBL6703402 | 0.95 | L3MBTL1 (0.42) | L3MBTL1NR1H4VDRMAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL5516308 | 0.94 | L3MBTL1 (0.41) | L3MBTL1NR1H4VDRMAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL5514407 | 0.94 | L3MBTL1 (0.43) | L3MBTL1NR1H4VDRMAPTCYP2C9 | |
| SCHEMBL14383766 | 0.93 | L3MBTL1 (0.43) | L3MBTL1NR1H4VDRMAPTCYP2C9 | |
| SCHEMBL6699590 | 0.92 | L3MBTL1 (0.42) | L3MBTL1NR1H4VDRCYP2C9KCNH2 | |
| Hydrochloric Acid SCHEMBL5510313 | 0.92 | L3MBTL1 (0.43) | L3MBTL1NR1H4VDRMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-6770666-B2 | A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY | JAPAN TOBACCO INC. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | L3MBTL1 4672/4885NR1H4 37/4885VDR 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.